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Abstract
Background: Although paclitaxel is a frontline antineoplastic agent for treatment of solid tumors, the paclitaxel-
evoked pain syndrome is a serious problem for patients. There is currently no valid drug to prevent or treat the
paclitaxel-induced allodynia, partly due to lack of understanding regarding the cellular mechanism. Studies have
shown that minocycline, an inhibitor of microglia/macrophage, prevented neuropathic pain and promoted
neuronal survival in animal models of neurodegenerative disease. Recently, Cata et al also reported that
minocycline inhibited allodynia induced by low-dose paclitaxel (2 mg/kg) in rats, but the mechanism is still unclear.
Results: Here, we investigate by immunohistochemistry the change of intraepidermal nerve fiber (IENF) in the hind
paw glabrous skin, expression of macrophage and activating transcription factor 3 (ATF3) in DRG at different time
points after moderate-dose paclitaxel treatment (cumulative dose 24 mg/kg; 3 × 8 mg/kg) in rats. Moreover, we
observe the effect of minocycline on the IENF, macrophages and ATF3. The results showed that moderate-dose
paclitaxel induced a persisted, gradual mechanical allodynia, which was accompanied by the loss of IENF in the
hind paw glabrous skin and up-regulation of macrophages and ATF3 in DRG in rats. The expressions of ATF3
mainly focus on the NF200-positive cells. More importantly, we observed that pretreatment of minocycline at dose
of 30 mg/kg or 50 mg/kg, but not 5 mg/kg, prevented paclitaxel-evoked allodynia. The evidence from
immunohistochemistry showed that 30 mg/kg minocycline rescued the degeneration of IENF, attenuated
infiltration of macrophages and up-regulation of ATF3 induced by paclitaxel treatment in rats.
Conclusions: Minocycline prevents paclitaxel-evoked allodynia, likely due to its inhibition on loss of IENF,
infiltration of macrophages and up-regulation of ATF3 in rats. The finding might provide potential target for
preventing paclitaxel-induced neuropathic pain.
Background
Clinical and animal research have shown that paclitaxel,
aw i d e l yu s e dc h e m o t h e r a p e u t i ca g e n ta g a i n s ts o l i d
tumors, can induce a dose-dependent peripheral sensory
neuropathy [1,2]. Subjects following application of pacli-
taxel mainly experience tingling and allodynia that often
occur in a “glove and stocking” distribution [3]. The
anti-tumor action of paclitaxel was due to their binding
tob-tubulin of microtubules. It has been thought that
such binding impaired axoplasmic transport, thereby
leading to a progressive, dying-back axonopathy [4].
Moreover, Siau et al reported that application of low-
dose paclitaxel (2 mg/kg) induced the loss of intraepi-
dermal nerve fibers (IENF) on day 31 after the first
injection [5]. Although quantification of IENF is poten-
tially an important tool to assess the occurrence and
severity of neuropathy [6], the correlation between the
loss of IENF and painful neuropathy induced by pacli-
taxel remains unclear.
There are no well-established treatments to prevent or
minimize paclitaxel-induced neuropathic pain because
of lack of cellular mechanism. Many factors such as
generation of radicals [7], abnormal functions of calcium
channel [8] and transient receptor potential vanilloid 4
(TRPV4) [9] have been reported to be attributed to the
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Recently, researchers find that paclitaxel also exerts
effects on the immune system and displays immunomo-
dulatory traits [10]. For example, paclitaxel can led to
infiltration of macrophages in DRG and microglia acti-
vation in spinal dorsal horn [11]. In addition, study also
shows that application of minocycline, a selective micro-
glia/macrophage inhibitor, prevents mechanical allodynia
induced by paclitaxel at a low dosage of 2 mg/kg [12].
Furthermore, it has been suggested that minocycline
protect the axonal dieback induced by spinal cord injury
[13]. However, the mechanisms underlying the blockage
of paclitaxel-induced allodynia by minocycline are still
poorly understood.
Therefore, in the present study, we first observe
whether moderate-dose paclitaxel (cumulative dose 24
mg/kg; 3 × 8 mg/kg, the dose was calculated from doses
clinically used) could induce allodynia, reduce the den-
sity of IENF in the hind paw glabrous skin and increase
expression of macrophages and ATF3 in DRG. Further-
more, we aim to elucidate whether minocycline treat-
ment also blocks allodynia induced by moderate-dose
paclitaxel. Specifically, effects of minocycline on the
density of IENF in the hind paw glabrous skin,
expression of cell injury marker (ATF3) and infiltration
of macrophages in DRG at different time points follow-
ing paclitaxel treatment are investigated.
Result
Minocycline prevented paclitaxel-induced mechanical
allodynia
The administration of paclitaxel at a cumulative dose of
24 mg/kg (3 × 8 mg/kg, 3 days apart, i.p) caused a
marked and prolonged mechanical allodynia as evi-
denced by 50% withdrawal threshold compared with day
0( P < 0.05). On day 4 and 12 following initial paclitaxel
treatment, the 50% withdrawal threshold significantly
reduced to 8.87 ± 1.33 g and 3.03 ± 1.92 g respectively
compared with the value (17.28 ± 1.85 g) on day 0
(Figure 1). Application of minocycline at a daily dosage
of 30 mg/kg or 50 mg/kg, but not 5 mg/kg, initiated
one day before paclitaxel and continued for 8 days sig-
nificantly attenuated mechanical allodynia on day 4, 8
(P <0 . 0 5 )a n d1 2( P < 0.01) compared with the paclitaxel
group. Furthermore, 50% withdrawal threshold had no
significantly difference between the 30 mg/kg minocy-
cline/paclitaxel group and the 50 mg/kg minocycline/
paclitaxel group or the vehicle group. Continuous
Figure 1 Minocycline blocked the paclitaxel-induced mechanical allodynia. Application of paclitaxel (cumulative dose 24 mg/kg; 3 ×
8 mg/kg) induced a marked and prolonged mechanical allodynia. On day 4, 8 and 12 after first paclitaxel treatment, the paclitaxel rats showed a
significant decrease in 50% withdrawal threshold relative to the vehicle group. *P < 0.05; **P < 0.01. Minocycline pretreatment at dose of
30 mg/kg or 50 mg/kg significantly attenuated paclitaxel-induced mechanical allodynia compared with the corresponding time points of
paclitaxel group, respectively. # P < 0.05; ##P < 0.01 and † P < 0.05; †† P < 0.01. However, 50% withdrawal threshold had no significant
difference between the 30 mg/kg minocycline/paclitaxel group and the 50 mg/kg minocycline/paclitaxel group or the vehicle group.
Minocycline at 30 mg/kg alone had no effect on the mechanical withdrawal threshold in control animals (n = 8/group).
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Page 2 of 8injection of minocycline at a dose of 30 mg/kg alone had
no effect on mechanical hypersensivity in rats (Figure 1),
so the dose of 30 mg/kg of minocycline was applied in
subsequent experiments.
Minocycline rescued the loss of IENF induced by
paclitaxel
Consistent with previous studies [5], PGP9.5-labeled
IENF emerged from cutaneous nerves and traveled verti-
cally into the epidermis where they branched into term-
inal (Figure 2A). Following application of paclitaxel, there
was a gradual decrease in the number of IENF (Figure 2H).
The number of IENF per sight decreased from 12.71 ± 1 in
vehicle rats to 11.92 ± 0.88, 6.2 ± 0.86, 4.5 ± 0.82 and 2.7 ±
0.53 on day 2, 4, 8 and 12 after paclitaxel treatment, respec-
tively (Figure 2B-E). However, application of minocycline
significantlyinhibited the loss ofIENF induced by paclitaxel
on day 4 (10.69 ± 0.64) and 12 (8.58 ± 0.66) compared with
that of paclitaxel group respectively (P <0 . 0 1 )( F i g u r e2 F
and 2G). Vehicle or minocycline alone did not affect the
density of IENF compared with normal rats (data not
shown).
Minocycline inhibited the increase in the number of
ATF3-IR positive cells induced by paclitaxel in DRG
To assess whether the loss of IENF is accompanied by
the sensory cell injury. We examined the levels of ATF3
in DRG at various time points. The result showed that
paclitaxel treatment significantly increased the number
of ATF3-immunoreactivity (IR) positive cells in L4 DRG
(Figure 3B-E and 3H) compared with vehicle-treated
rats in that ATF3-IR positive cells were hardly found
(Figure 3A). Meanwhile, double immunofluorescence
staining showed that ATF3 was co-localized with
NF200-labeled cells (A fiber neuronal marker), but not
with IB4-labeled cells (C fiber neuronal marker) or
GFAP-labeled cells (satellite cell marker) (Figure 4).
Furthermore, pretreatment with minocycline inhibited
the increase of ATF3 (0.44 ± 0.18 and 1.33 ± 0.50 in
minocycline/paclitaxel group versus 12.44 ± 1.68 and
24.33 ± 2.12 in paclitaxel group on day 4 and 12,
respectively) (Figure 3F and 3G).
Minocycline inhibited infiltration of macrophages induced
by paclitaxel in DRG
Few macrophages stained by ED1 were detected in L4
DRG of vehicle treated rats (Figure 5A). However, fol-
lowing paclitaxel treatment, a significant increase in the
number of macrophages was observed in DRG on day 2
(16.83 ± 1.81), 4 (37.33 ± 1.30), 8 (50.66 ± 2.66) and 12
(77.66 ± 1.62) (Figure 5B-E). Furthermore, the infiltra-
tion of macrophages induced by paclitaxel was signifi-
cantly inhibited by minocycline treatment on day 4
(Figure 5F) and 12 (Figure 5G). Because recent study
Figure 2 Minocycline inhibited paclitaxel-induced loss of IENF. PGP9.5-staining shows epidermal innervation in the hind plantar paw skin of
normal rats (A). Continuous loss of PGP9.5 positive nerve fibers is evident on day 2-12 following paclitaxel treatment (B-E), *P < 0.05; **P < 0.01
compared with the vehicle group. Minocycline pretreatment attenuated the loss of IENF (F, G), ##P < 0.01 compared with paclitaxel group at
corresponding time points. Histogram represents the mean number of IENF per sight under various treated conditions (H) (n = 5/group).
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Page 3 of 8Figure 3 Minocycline reduced up-regulation of ATF3 in DRG induced by paclitaxel. No ATF3-positive cells in L4 DRG were observed in the
vehicle-treated rats (A). Following application of paclitaxel, there is a progressive and significant increase in the number of ATF3 positive cells in
DRG (B-E), while in minocycline/paclitaxel-treated rats, ATF3 positive cells were significantly decreased (F, G). Histogram representing the mean
number of ATF3 positive cells under various treated conditions (H). **P < 0.01 compared with the corresponding time points of paclitaxel group
(n = 5/group).
Figure 4 Double immunofluorescence staining showed colocalization of activating transcription factor 3 (ATF3) with neurofilament
200 (NF200). Upregulated ATF3 induced by paclitaxel was co-localized with NF200-labeled cells (A-C), but not with IB4-labeled cells (D-F) or
GFAP-labeled cells (G-I).
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cord played a vital role in neuropathic pain [14], we also
examined whether paclitaxel could induce the macro-
phage to infiltrate into the spinal cord. However, in our
experiment, no obvious ED1-positive cells were detected
in the spinal dorsal horn in either paclitaxel group or
vehicle group (data not shown).
Discussion
In the present study, we reported that moderate-dose
paclitaxel induced mechanical allodynia, accompanied
by partial loss of IENF in the hind paw glabrous skin,
up-regulation of ATF3 and macrophages infiltration in
DRG. Further results showed that minocycline, an inhi-
bitor of microglia/macrophage activation, inhibited the
loss of IENF as well as the increase of ATF3 and macro-
phages infiltration in DRG. Such inhibitory action of
minocycline is parallel with its prevention of paclitaxel-
induced allodynia. Our observations firstly implied that
inhibition on loss of IENF and macrophages infiltration
might contribute to the minocycline preventive effect on
paclitaxel-induced allodynia.
Impact of paclitaxel on IENF and macrophage
It is well established that paclitaxel treatment could eli-
cit peripheral sensory neuropathy. Degeneration of ner-
vous fibers has been currently suggested as the possible
mechanism underlying the paclitaxel induced mechani-
cal allodynia. It has been reported that application of
low-dose paclitaxel (2 mg/kg) induced the loss of IENF
[5,15]. In vitro study also showed that paclitaxel directly
applied to the axonal resulted in degeneration of axons
[16]. In our present study, moderate-dose paclitaxel (8
mg/kg) also significantly decreased the number of IENF.
There are several explanations to such degeneration
of fibers. For example, Nogales et al indicated that
paclitaxel impaired axoplasmic transport by binding
tob-tubulin which has been thought as the cause result-
ing in degeneration of IENF [17]. While evidence against
this hypothesis implied that paclitaxel directly impaired
mitochondria function which might lead to degeneration
of the fiber terminals [2].
We also found that paclitaxel induced the expression
of ATF3 in DRG. It has been shown that ATF3 might
have a survival/regenerative function in sensory neurons
[18]. Evidence has shown that lack of target derived
growth factors secondary to nerve injury resulted in the
ATF3 up-regulation [19,20]. Therefore, in our study, it
appeared that the decreased availability of target-derived
growth factors due to the degeneration of IENF follow-
ing paclitaxel administration induced expression of
ATF3. In addition, double-staining showed that expres-
sion of ATF3 mainly focused on the NF200-positive
cells, the result indicated that paclitaxel mainly induced
the injury of Ab-fiber neurons and is consistent with
Dougherty’s report that paclitaxel treatment in cancer
patients impairs the Ab fiber function [21].
In the present study, we also observed marked hyper-
plasia of macrophage in the DRG following application
of paclitaxel. The result is consistent with Peter’s report
that intravenous infusion of high-dose paclitaxel induced
hypertrophy and hyperplasia of macrophage in DRG and
sciatic nerve [22]. The increased macrophages observed
in the current study may be due to infiltration of macro-
phages into the DRG. This hypothesis is supported by
our latest observation that application of moderate-dose
paclitaxel elevated the level of chemotatic factor in DRG
(unpublished data). Functionally, the activated macro-
phage may help remove degeneration neuronal debris
and myelin following the peripheral nerve injury [23];
on the other hand, it may also contribute to the patho-
logical pain through the release of proinflammatory
Figure 5 Minocycline inhibited infiltration of macrophages into DRG induced by paclitaxel. There is a significant increase on days 4, 8 and
12 in the number of ED-1 positive cells in L4 DRG after paclitaxel treatment (B-E), *P < 0.05;**P < 0.01 compared with the vehicle group. ED-1
positive cells in minocycline/paclitaxel-treated rats were significantly decreased compared with the corresponding time points of paclitaxel
group, ##P < 0.01 (F, G). Histogram represents the mean number of ED-1 positive cells under various treated conditions (H) (n = 5/group).
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ent neurons [24,25].
Role of Minocycline in degeneration of IENF and
infiltration of macrophages induced by paclitaxel
Cata’s study showed that minocycline, an inhibitor of
microglia/macrophage activation, ameliorated taxol-
induced hyperalgesia. It has been hypothesized that the
immunomodulatory activity of minocycline underlies its
protective effect on taxol-induced neuropathic pain.
However, the exact mechanism is still unclear. In our
present study, minocycline attenuated the loss of IENF,
which was parallel with the reduced allodynia. It has
been shown that minocycline decreased recruitment and
activation of macrophage thereby slowing Wallerian
degeneration [26]. In addition, minocycline treatment
reduces oligodendrocyte death and attenuates axonal
dieback after spinal cord injury [13]. Moreover, mito-
chondrial impairment, which has been suggested to con-
tribute to degeneration of nerve fibers, could be
prevented by minocycline. Therefore, it is possible that,
by protecting the integrity of IENF, minocycline attenu-
ated the loss of IENF induced by paclitaxel. This
hypothesis was also supported by our present finding
that minocycline decreased ATF3 up-regulation in DRG
neurons.
Furthermore, we observed that paclitaxel-induced
macrophages infiltration into DRG was obviously pre-
vented in minocycline treated rats. Several lines of evi-
dence proved that minocycline could inhibit the
activation and migration of macrophages and reduce
production of macrophage proinflammatory factors
[27,28] which mediated peripheral nerve degeneration
[ 2 8 ] .F u r t h e r m o r e ,i n h i b i t ion of macrophage responses
might prevent nerve fiber degeneration by prohibiting
the phagocytosis of axon ends [13,28]. Although in the
present study, activation of macrophages around the
peripheral nerve fibers was not examined, its destructive
effect on the IENF could not be excluded. Therefore,
inhibition of macrophage responses might contribute to
minocycline preventive effect on IENF loss induced by
paclitaxel. However, additional studies are needed to
elucidate the role of minocycline in protecting IENF
from paclitaxel-induced injury.
Conclusions
In conclusion, our present data provided evidence that
allodynia evoked by moderate-dose paclitaxel might be
associated with the degeneration of IENF and recruit-
ment of macrophages. Importantly, inhibition of mino-
cycline on paclitaxel-induced allodynia might be
mediated by interruption of loss of IENF and macro-
phage responses. Minocycline, a well-tolerated and
widely used clinical drug, might represent a potential
agent for preventing paclitaxel-induced neuropathic pain
and subsequently improving patients’ outcome.
Methods
Experimental Animals
Male Sprague-Dawley rats weighting 220-280 g were
purchased from the laboratory animal center of Sun
Yat-Sen University, the permit number for this study is
SCXK(Guangdong)2009-0011. All animal experimental
procedures were approved by the Sun Yat-Sen Univer-
sity Animal Care and Use Committee and were carried
out in accordance with the guideline of the National
Institutes of Health on animal care and the ethical
guidelines. The minimum number of animals was used
in each experiment, and in all cases every effort was
made to minimize any pain and suffering in the subject
animals.
Drug administration
Paclitaxel (Taxol, Bristol-Myers Squibb, 6 mg/ml) was
d i l u t e dw i t hs a l i n e( 1 : 3 )a n di n j e c t e di . p( c u m u l a t i v e
dose of 24 mg/kg) on 3 alternate days (days 1, 4 and 7)
[29]. Minocycline (Sigma) was administered (i.p) daily at
ad o s a g eo f3 0m g / k ga n db e g i np r i o ro n ed a yt ot h e
paclitaxel [30]. Rats received minocycline always 30 min
before application of paclitaxel and continued up to
eight days. Minocycline was dissolved in saline and
stored in solution at 200 mg/ml and then diluted in sal-
ine before the administration.
Behavioral testing
The rats were accommodated to the testing environ-
ment by placement within testing chambers for 15-20
minutes on the three separate days just prior to drug
administration. Mechanical sensitivity was assessed
using von Frey hairs as described previously [12]. Briefly,
rats were placed under three different transparent Plexi-
glas chambers positioned on a wire mesh floor. Fifteen
minutes were allowed for habituation. Each stimulus
consisted of a 2-3s application of the von Frey hair to
t h em i d d l eo fp l a n t a rs u r f a c eo ft h ef o o tw i t h5m i n
interval between stimuli. Brisk withdrawal or licking of
the paw following the stimulus was considered a positive
response. The experimenter who conducted the beha-
vioral tests was blinded to all treatments.
Immunohistochemistry
All rats used in the immunohistochemistry experiments
had confirmed to have a characteristic of behavior. Rats
were deeply anesthetized with urethane (1.5 mg/kg, i.p.)
at different time points, the chest was opened, and then
quickly perfused through the ascending aorta with a
warm heparinized saline, followed by 4% paraformalde-
hyde in 0.1 M phosphate buffer, pH 7.2-7.4, 4°C. The
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Page 6 of 8glabrous skin of hind paw and the L4 DRG was excised,
post-fixed overnight and cryoprotected for 24 h in 30%
sucrose in PB. Cryostat sections (16 μm) were cut and
processed for immunohistochemical staining as pre-
viously described [31,32]. Sections were blocked with 3%
donkey serum in 0.3% Triton X-100 for 1 hour at the
room temperature, and then incubated overnight at 4°C
with rabbit anti-protein gene product 9.5 primary anti-
body (PGP9.5, 1:2000, Chemicon) for skin or rabbit
anti-ATF3 antibody (1:200, Santa Cruz) or mouse anti-
Macrophage antibody (ED-1, 1:200, Chemicon) for
DRG. For double staining, the sections were incubated
with rabbit anti-ATF3 antibody (1:200, Santa Cruz) and
mouse anti-neurofilament-200, an A-fiber neuronal mar-
ker (NF200, 1:300, Chemicon), mouse anti-isolectin B4,
a C-fiber neuronal marker (IB4, 1:200, Sigma) or glial
fibrillary acidic protein, a satellite cell marker (mouse
anti-GFAP, 1:2000, Chemicon). After rinsing three times
with PBS, sections were incubated in donkey anti-rabbit
IgG secondary antibody labeled with Cy3 (1:500, Jack-
son) or a mixture of IgG secondary antibody labeled
with Cy3 and FITC respectively (1:500, Jackson) for 1 h
at a room temperature. Five rats were included for each
group for immunohistochemistry quantification. Three
DRG tissue sections per animal are randomly selected,
t h en u m b e ro fA T F 3o rE D - 1p o s i t i v ec e l l sw a se x a m -
ined with a Leica (Leica, Germany) fluorescence micro-
scope and images were captured with a Leica DFC350
FX camera. For IENF quantification, we selected five
plantar skin sections per animal and chose three sights
for each section randomly. Images of immunohisto-
chemical results were obtained using an Zeiss LSM710
confocal microscope and analyzed with a Bitplane Imaris
V6.4. All ascending nerve fibers that were seen to cross
into the epidermis were counted, no minimum length
was required and fibers that branched within the epider-
mis were counted as one. The number of IENF per
sight was counted. To confirm the specificity of the pri-
mary antibody, control sections were incubated without
primary antiserum.
Statistical analysis
Blinded evaluator analyzed all images. The number of
the fibers, ATF3 or ED1 positive cells every sight was
expressed as mean ± SEM. Data were compared with
student’st - t e s t ,P < 0.05 was considered significant. For
behavioral experiments, one-way ANOVA followed by
post hoc test was used and P < 0.05 was considered
significant.
Abbreviations
IENF: intraepidermal nerve fiber; ATF3: activating transcription factor 3; DRG:
dorsal root ganglion; TRPV4: transient receptor potential vanilloid 4.
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